Low Dose Naltrexone: What It Is and When It Helps

Low Dose Naltrexone (LDN) is one of the more interesting medications in modern off-label medicine. It is generic, inexpensive, has decades of safety data at higher doses, and has accumulated meaningful evidence for a range of conditions that conventional medicine struggles with — autoimmune disease, fibromyalgia, chronic pain, inflammatory bowel disease, and increasingly, long COVID and post-viral syndromes. It is also genuinely under-prescribed, partly because the regulatory pathway for repurposing existing drugs is broken, and partly because most physicians simply have not encountered it during their training.

This article walks through what LDN actually is, how it works, what conditions it may help, and what to realistically expect. The goal is to give you the foundation to have an informed conversation with a prescribing physician — not to replace that conversation.

What naltrexone is, in its standard form

Naltrexone is an opioid receptor antagonist developed in the 1960s and FDA-approved in 1984 for the treatment of opioid use disorder and later alcohol dependence. The standard dose is 50 mg daily. At this dose, naltrexone fully blocks opioid receptors, which prevents the rewarding effects of opioids and reduces alcohol cravings. It has decades of safety data at the standard dose and is widely used in addiction medicine.

The story of Low Dose Naltrexone begins in the 1980s with Dr. Bernard Bihari, a New York physician working with HIV patients before effective antiretroviral therapy existed. Bihari noticed that low doses of naltrexone — well below the FDA-approved 50 mg — appeared to improve immune function in his patients. He extended the observation to autoimmune disease, multiple sclerosis, and chronic pain conditions. His clinical work over decades established the foundation that subsequent researchers built on.

How LDN works mechanistically

The mechanism of LDN is genuinely different from standard naltrexone, and understanding it helps explain why it has such a wide range of potential applications.

At low doses (1.5 to 4.5 mg), naltrexone briefly blocks opioid receptors for several hours. The body responds to this blockade by upregulating production of endogenous opioids — particularly beta-endorphin and met-enkephalin. By the time the blockade wears off (which it does within hours at low doses), the body has produced more endogenous opioids than it had before. The net effect is a sustained increase in endogenous opioid signaling.

This increase has multiple downstream effects. Endogenous opioids modulate immune function — particularly T-cell balance and natural killer cell activity. They affect mood and pain perception. They appear to influence inflammatory cytokine production.

The second key mechanism is microglial modulation. Microglia are the immune cells of the central nervous system, and chronic microglial activation contributes to neuroinflammation in many conditions: fibromyalgia, chronic pain syndromes, multiple sclerosis, complex regional pain syndrome, and increasingly recognized in long COVID and post-viral syndromes. LDN appears to dampen pathological microglial activation through Toll-like receptor 4 antagonism — a pathway distinct from its opioid receptor effects.

The combination of endogenous opioid upregulation and microglial modulation gives LDN a uniquely broad therapeutic profile. It is not addressing one specific receptor or pathway in isolation; it is modulating two interconnected systems that go awry in many chronic conditions.

What conditions LDN may help

The evidence base for LDN is heterogeneous across conditions. Some applications have substantial published evidence; others rely primarily on accumulated clinical experience and mechanistic plausibility. The honest picture:

Fibromyalgia. Multiple randomized controlled trials have demonstrated meaningful pain reduction and functional improvement with LDN, with effect sizes comparable to or better than commonly used fibromyalgia medications. This is one of the better-supported indications.

Inflammatory bowel disease (Crohn’s and ulcerative colitis). Small RCTs and substantial clinical experience support LDN as adjunctive therapy in IBD. Some patients achieve meaningful symptom reduction; others see modest benefit. Best used alongside, not in place of, conventional IBD therapy.

Multiple sclerosis. The evidence is mixed but suggests potential benefit for symptom management and possibly disease modification. LDN has been used in MS for over two decades, primarily by patients seeking complementary therapy alongside disease-modifying drugs.

Hashimoto’s thyroiditis. Smaller evidence base than the conditions above, but reasonable mechanistic rationale (immune modulation) and accumulating clinical experience suggest reduced antibody levels and improved well-being in some patients.

Chronic fatigue syndrome / ME-CFS. Clinical experience and small studies support a role, though larger trials are limited. The mechanism (microglial modulation) aligns with current understanding of CFS pathophysiology.

Long COVID and post-viral syndromes. Emerging evidence and rapidly accumulating clinical experience suggest benefit for a meaningful subset of patients. The microglial inflammation hypothesis for long COVID aligns with LDN’s mechanism. Multiple practitioners report meaningful response in approximately 50 percent of long COVID patients trialed on LDN. This is a fast-evolving area.

Complex regional pain syndrome (CRPS). Clinical experience supports use as part of multi-modal CRPS management.

Other autoimmune conditions. Lupus, rheumatoid arthritis, psoriasis, ankylosing spondylitis, and others have smaller evidence bases but reasonable mechanistic rationale. Use as complement to specialist-directed therapy, not as replacement.

Other chronic pain conditions. Some patients with chronic pain not responsive to standard therapy may benefit from LDN as part of multi-modal pain management.

What LDN does not do

LDN is not a cure for any of these conditions. It does not produce dramatic transformations. It is not a substitute for appropriate specialty care in serious autoimmune disease. Patients who respond may achieve meaningful symptom reduction and improved quality of life — typically in the range of 30 to 60 percent improvement in symptom burden — but full remission is uncommon. Patients should expect realistic outcomes, not miraculous ones.

LDN does not work for everyone. Across conditions, response rates appear to be approximately 50 to 70 percent depending on the condition and patient population. This means a significant minority of patients trial LDN without meaningful benefit. There is currently no reliable way to predict who will respond.

How LDN is dosed and administered

LDN is taken orally as a compounded preparation, since the standard 50 mg pill is not divisible to the small doses needed. Compounding pharmacies prepare capsules at typical doses of 1.5, 3.0, or 4.5 mg.

The standard starting protocol is 1.5 mg nightly for 1 to 2 weeks, increasing to 3.0 mg nightly for another 1 to 2 weeks, then 4.5 mg nightly as the typical therapeutic target. Some patients do well at 3.0 mg and don’t need to titrate higher; some patients are sensitive and stay at 1.5 mg long-term; some patients tolerate higher doses (up to 6 mg) under physician guidance.

LDN is typically taken at bedtime because the brief opioid receptor blockade aligns with peak endogenous opioid production during sleep. Some patients who experience sleep disruption with bedtime dosing switch to early evening or morning, with comparable efficacy in clinical experience.

Side effects and considerations

LDN has a favorable safety profile compared to most medications used for the same conditions. The most common side effects are:

Vivid dreams or sleep disruption in the first 1 to 2 weeks of starting therapy. Often resolves as the body adjusts. Can be addressed with slower titration or earlier dosing.

Mild gastrointestinal upset in some patients during titration. Usually transient.

Headache in a minority of patients during initial weeks.

Severe side effects are rare. LDN does not cause the addiction, sedation, cognitive impairment, or other adverse effects associated with many conventional pain or autoimmune medications.

Important contraindication: LDN cannot be combined with opioid pain medications. It will block their effect. Patients on chronic opioid therapy must transition off opioids before starting LDN, which requires careful coordination with their pain management physician. Patients who anticipate needing opioid pain medication for surgery should pause LDN appropriately around the procedure.

Other considerations: Caution in significant liver disease (since naltrexone is hepatically metabolized). Pregnancy and breastfeeding are areas where the evidence is limited; we typically defer LDN in those contexts.

Who prescribes LDN

Despite the accumulating evidence, LDN is still substantially under-prescribed in conventional medicine. Most general practitioners, rheumatologists, and gastroenterologists do not prescribe it — partly because it is off-label, partly because it is not promoted by pharmaceutical companies (it is a generic compounded medication), and partly because it was not part of their training.

Physicians who do prescribe LDN tend to be in functional medicine, integrative medicine, pain medicine, or peptide-focused practices like ours. The LDN Research Trust maintains a directory of prescribing physicians for patients seeking knowledgeable prescribers.

If you are considering LDN, find a physician who actually prescribes it knowledgeably and can monitor response and adjust dosing — not a clinic that prescribes it as one of many bundled interventions without specific expertise.

What good LDN care looks like

Quality LDN prescribing involves:

Comprehensive baseline workup — appropriate labs to characterize your underlying condition, rule out competing diagnoses, and establish comparison values for monitoring.

Honest discussion of evidence — what the data actually says about your specific condition, realistic expectations for response, and what non-response would look like.

Standard titration with adjustment based on response — starting low, titrating to therapeutic dose, willing to adjust upward or downward based on tolerability and effect.

Coordination with your specialty care — communication with your rheumatologist, gastroenterologist, or other specialists when relevant. LDN works alongside specialty care, not in place of it.

Structured follow-up — assessment of response at 6 to 12 weeks, willingness to discontinue if no benefit, ongoing monitoring of relevant lab markers and patient-reported outcomes.

Realistic framing — willingness to discuss when LDN is or isn’t working, openness to changing course if needed.

Bottom line

Low Dose Naltrexone is one of the more interesting and under-prescribed medications in modern off-label medicine. The evidence base is heterogeneous across conditions but meaningful for several. The safety profile is favorable. The mechanism is plausible and increasingly well-characterized. The cost is low. The downside of trying it for an appropriate indication is small.

For patients with fibromyalgia, autoimmune disease, IBD, chronic pain, long COVID, or related inflammatory conditions who have not responded adequately to standard care, LDN is worth considering as part of an informed conversation with a prescribing physician. It will not work for everyone. When it works, the benefit can be substantial and durable.